Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial

作者：Gail J. Roboz, Hartmut Döhner, Christopher Pocock, Hervé Dombret, Farhad Ravandi, Jun Ho Jang, Dominik Selleslag, Jiřı́ Mayer, Uwe M. Martens, Jane L. Liesveld, Teresa Bernal, Ming Chung Wang, Peiwen Yu, Ling Shi, Shien Guo, Ignazia La Torre, Barry Skikne, Qian Dong, Julia Braverman, Salem Abi Nehme, C.L. Beach, Andrew H. Wei · 发表于：Haematologica · 年份：2021 · DOI：10.3324/haematol.2021.279174 · 被引用次数：16 · 研究领域：Acute Myeloid Leukemia Research、Histone Deacetylase Inhibitors Research、Autoimmune and Inflammatory Disorders Research

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial